HLB Stock Outlook 2026 (KOSDAQ 028300): Rivoceranib, the FDA Binary, and Extreme Volatility
HLB (KOSDAQ 028300) 2026 stock analysis: rivoceranib liver-cancer combination therapy and the single US FDA approval catalyst, CRL/manufacturing/partner risk, the complex HLB Group affiliate structure, retail-driven volatility, and how a clinical-stage Korean biotech binary differs from Celltrion, Samsung Biologics, and Alteogen.
HLB 028300 KOSDAQ